Superworth

Stoke Therapeutics EPS STOK

Diluted earnings per share by quarter and over the last twelve months, from 2018.

Last 12 months, to Jun 30, 2026
−$3.30
Latest quarter, Q2 FY26
−$0.93
Fiscal year 2025
−$0.08

Stoke Therapeutics' earnings per share was −$3.30 over the twelve months to Jun 30, 2026, down 488% on a year earlier.

In its latest quarter, Q2 FY26, it was −$0.93.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$0.08n/a
FY2024−$1.68n/a
FY2023−$2.37n/a
FY2022−$2.60n/a
FY2021−$2.32n/a
FY2020−$1.56n/a
FY2019−$9.00n/a
FY2018−$17.94n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.93n/a−$3.30
Q1 FY26−$0.79−142%−$2.77
Q4 FY25−$0.93n/a−$0.08
Q3 FY25−$0.65n/a$0.67
Q2 FY25−$0.40n/a$0.85
Q1 FY25$1.90n/a$0.79
Q4 FY24−$0.18n/a−$1.68
Q3 FY24−$0.47n/a−$2.10
Q2 FY24−$0.46n/a−$2.18
Q1 FY24−$0.57n/a−$2.41
Q4 FY23−$0.60n/a−$2.37
Q3 FY23−$0.55n/a−$2.42

Against its peers

Companies in Drug Manufacturers - General nearest Stoke Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
STOKStoke Therapeutics−$3.30−488% a year
PAHCPhibro Animal Health$2.44+107% a year
ANIPANI Pharmaceuticals$4.70
ANABAnaptysbio$4.57
PCRXPacira BioSciences$0.35
HRMYHarmony Biosciences$3.09−0% a year
OMEROmeros$1.52
PBHPrestige Consumer Healthcare$3.57−16% a year
AMPHAmphastar Pharmaceuticals$1.70−36% a year
NRIXNurix Therapeutics$2.31
ABUSArbutus Biopharma$0.78
Peer median$2.38

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Stoke Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.